oral semaglutide results 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial Oral Semaglutide, the First Ingestible

Solely for convenience, trademarks, trade names and service marks referred to in this Annual Report may appear without the , or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent permitted under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks

Multiple serum biomarkers have been described as potential indicators, not only to identify hepatocyte injury and necrosis but also to help predict patient outcomes based on presence or absence of certain intracellular or intramitochondrial markers

Stability: Long shelf-life under proper storage conditions

PMID: 25415472 Bajramagic S, Sever M, Rasic F, et al

Use with caution in patients with renal impairment

Bacterial load in samples was calculated using the experimentally derived C values and the standard curve equation